Fermenta Biotech Ltd — Updates, 04-06-2025: Company Update

Fermenta Biotech Limited has announced a board meeting to approve the financial results for the quarter and half-year. The company reported FY25 consolidated revenue of ₹481.3 Cr, up 39% year-on-year, driven by 48% growth in human nutrition and 24% in animal nutrition volumes. EBITDA rose 209% YoY to ₹121.6 Cr, with a margin expansion to 26% due to cost controls and higher realizations. Profit after tax improved significantly to ₹76.4 Cr. The German and US subsidiaries showed strong revenue growth, with the German unit turning profitable. Fermenta advanced new Vitamin D3 formulations, including plant-based variants, initiating qualification with global customers. The company reduced debt by 17%, improved liquidity, and strengthened its balance sheet, positioning for scalable growth.